Nicholas Sellke^1,2,*, Erin Jesse^1,2, Justin M. Dubin³, Tomislav D. Medved^1,2, Neha S. Basti⁴, Janvi Ramchandra², Robert E. Brannigan⁴, Joshua A. Halpern⁴, Nannan Thirumavalavan^1,2

Canadian Journal of Urology, Vol.32, No.2, pp. 89-94, 2025, DOI:10.32604/cju.2025.065004 - 30 April 2025

Abstract Introduction: Direct-to-consumer (DTC) telemedicine has emerged as an option for transgender patients seeking gender affirming hormone therapy (GAHT). We aimed to characterize the healthcare services provided by DTC telemedicine companies offering GAHT and to compare their costs to a tertiary care center. Methods: We identified DTC telemedicine platforms offering GAHT via internet searches and extracted information from their websites related to evaluation, treatment, monitoring, and cost. Cost of the DTC GAHT was compared to cost for comparable services at a tertiary care center. Results: Six DTC companies were identified. All platforms utilized an informed consent model… More >

Zachariah Taylor^1,*, Kayla Meyer², Danielle Terrenzio², Ryan Wong³, Sharon Larson⁴, Stephanie Kjelstrom⁴, Natalina Contoreggi⁵, Laurence Belkoff^1,6, Ilia Zeltser^1,6

Canadian Journal of Urology, Vol.32, No.1, pp. 21-27, 2025, DOI:10.32604/cju.2025.064705 - 20 March 2025

Abstract Purpose: While the mental health impact of a prostate cancer diagnosis, including low-risk prostate cancer, is well-documented, the effect of pre-existing anxiety and/or depression on adherence to active surveillance protocols in low-risk prostate cancer patients remains unclear. This study assessed the association between prior anxiety and/or depression and active surveillance adherence in men with low-risk prostate cancer. Methods: We conducted a retrospective, multicenter study involving 426 men diagnosed with low-risk prostate cancer who were recommended active surveillance as the primary management strategy. Active surveillance adherence was defined by completion of both a prostate-specific antigen test… More >

Kazuyoshi Kawakami^*, Takashi Yokokawa^*, Kazuo Kobayashi^*, Takahito Sugisaki^*, Kenichi Suzuki^*, Mitsukuni Suenaga^†, Kensei Yamaguchi^†, Ayaka Inoue^‡, Yoshiaki Machida^‡, Toshiharu Yamaguchi^†, Toshihiro Hama^*

Oncology Research, Vol.25, No.9, pp. 1625-1631, 2017, DOI:10.3727/096504017X15012905098071

Abstract Adherence has become an important issue in modern oncology treatment. Most studies have included heterogeneous target tumor types, regimens, and therapy settings. Our study focused on capecitabine during capecitabine plus oxaliplatin (XELOX) treatment as an adjuvant therapy for colorectal cancer. The main aims of this study were to evaluate real-life adherence to capecitabine and to investigate candidate factors that might decrease adherence. We studied 338 consecutive patients who received XELOX treatment between December 1, 2011, and April 30, 2015, at the Cancer Institute Hospital of the Japanese Foundation for Cancer Research. Our study assessed adherence… More >